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Abstract
Aim:  To  evaluate  the  effects  of  three  different  doses  of  gabapentin  pretreatment  on  the  inci-
dence and  severity  of  myoclonic  movements  linked  to  etomidate  injection.
Method:  One  hundered  patients,  between  18  and  60  years  of  age  and  risk  category  American
Society of  Anesthesiologists  I--II,  with  planned  elective  surgery  under  general  anesthetic  were
included in  the  study.  The  patients  were  randomly  divided  into  four  groups  and  2  h  before  the
operation were  given  oral  capsules  of  placebo  (Group  P,  n  =  25),  400  mg  gabapentin  (Group  G400,
n =  25),  800  mg  gabapentin  (Group  G800,  n  =  25)  or  1200  mg  gabapentin  (Group  G1200,  n  =  25).
Side effects  before  the  operation  were  recorded.  After  preoxygenation  for  anesthesia  induction
0.3 mg  kg−1 etomidate  was  administered  for  10  s.  A  single  anesthetist  with  no  knowledge  of  the
study medication  evaluated  sedation  and  myoclonic  movements  on  a  scale  between  0  and  3.
Two minutes  after  induction,  2  g  kg−1 fentanyl  and  0.8  mg  kg−1 rocuronium  were  administered
for tracheal  intubation.
Results:  Demographic  data  were  similar.  Incidence  and  severity  of  myoclonus  in  Group  G1200
and Group  G800  were  signiﬁcantly  lower  than  in  Group  P;  sedation  incidence  and  level  were
appreciably  higher  compared  to  Group  P  and  Group  G400.  While  there  was  no  difference  in  the∗ Corresponding author.
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incidence  of  myoclonus  between  Group  P  and  Group  G400,  the  severity  of  myoclonus  in  Group
G400 was  lower  than  in  the  placebo  group.  In  the  two-hour  period  before  induction  other  than
sedation  none  of  the  side  effects  related  to  gabapentin  were  observed  in  any  patient.
Conclusion:  Pretreatment  with  800  mg  and  1200  mg  gabapentin  2  h  before  the  operation
increased  the  level  of  sedation  and  reduced  the  incidence  and  severity  of  myoclonic  movements
due to  etomidate.
©  2015  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Efeito  do  pré-tratamento  com  gabapentina  sobre  a  mioclonia  após  etomidato:  um
estudo  randômico,  duplo-cego  e  controlado  por  placebo
Resumo
Objetivo:  Avaliar  os  efeitos  de  três  doses  diferentes  de  gabapentina  como  pré-tratamento  sobre
a incidência  e  gravidade  dos  movimentos  mioclônicos  associados  à  injec¸ão  de  etomidato.
Método:  Cem  pacientes,  com  idades  entre  18-60  anos,  estado  físico  ASA  I-II,  programados  para
cirurgia eletiva  sob  anestesia  geral  foram  incluídos  no  estudo.  Os  pacientes  foram  randomica-
mente divididos  em  quatro  grupos  e,  2  horas  antes  da  operac¸ão,  receberam  cápsulas  orais  de
placebo (Grupo  P,  n  =  25),  400  mg  de  gabapentina  (Grupo  G400,  n  =  25),  800  mg  de  gabapentina
(Grupo  G800,  n  =  25)  ou  1200  mg  de  gabapentina  (Grupo  G1200,  n  =  25).  Os  efeitos  colaterais
antes da  cirurgia  foram  registados.  Após  pré-oxigenac¸ão  para  a  induc¸ão  da  anestesia,  etomidate
(0,3 mg.kg−1)  foi  administrado  por  10  segundos.  Um  único  anestesista,  cego  para  a  medicac¸ão
do estudo,  avaliou  a  sedac¸ão  e  os  movimentos  mioclônicos  usando  uma  escala  de  0  a  3.  Dois
minutos  após  a  induc¸ão,  fentanil  (2  gr.kg−1)  e  rocurônio  (0,8  mg.kg−1)  foram  administrados
para a  intubac¸ão  traqueal.
Resultados:  Os  dados  demográﬁcos  foram  semelhantes.  A  incidência  e  gravidade  da  mioclonia
nos grupos  G1200  e  G800  foram  signiﬁcativamente  menores  que  no  Grupo  P;  a  incidência  e
o nível  de  sedac¸ão  foram  consideravelmente  maiores  comparados  ao  Grupo  P  e  Grupo  G400.
Enquanto  não  houve  diferenc¸a  na  incidência  de  mioclonia  entre  os  grupos  P  e  G400,  a  gravidade
da mioclonia  no  Grupo  G400  foi  menor  que  no  grupo  placebo.  No  período  de  2  horas  antes
da induc¸ão,  nenhum  dos  efeitos  colaterais  relacionados  à  gabapentina,  exceto  sedac¸ão,  foi
observado em  qualquer  paciente.
Conclusão:  O  pré-tratamento  com  800  mg  e  1200  mg  de  gabapentina  2  horas  antes  da  operac¸ão
aumentou o  nível  de  sedac¸ão  e  reduziu  a  incidência  e  gravidade  dos  movimentos  mioclônicos
associados  ao  etomidato.
©  2015  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Etomidate,  a  derivative  of  imidazole,  is  a  popular  hypnotic
agent  chosen  for  patients  with  cardiovascular  instability  due
to  minimal  cardiovascular  side  effects  and  extremely  stable
hemodynamic  proﬁle.  Myoclonus  and  injection  pain  are  two
disagreeable  side  effects  of  anesthesia  induction  with  eto-
midate.  As  many  side  effects  due  to  etomidate  are  thought
to  be  linked  to  the  solvent  propylene  glycol,  a  lipid  formula-
tion  was  developed.  While  this  new  formulation  prevented
injection  pain,  venous  irritation  and  hemolysis,  myoclonus
incidence  was  not  affected  by  the  solvent.1The  formation  of  myoclonus  during  anesthesia  induction
with  etomidate  has  clinical  importance  in  select  groups
of  patients.  Myoclonus  can  increase  the  risk  of  regurgi-
tation  and  aspiration  in  patients  with  full  stomach,  as  it
o
e
pncreases  intraocular  pressure  it  may  cause  vitreous  prolapse
n  patients  with  open  eye  injuries,  and  as  myocardial  oxy-
en  consumption  increases  during  myoclonus  it  may  cause
roblems  in  patients  with  limited  cardiovascular  reserves.2
inally  myoclonus  has  been  observed  to  be  responsible  for
ypoxemia  attacks  during  spontaneous  respiration  when
tomidate  is  administered  for  sedation.2,3 Despite  the  vari-
ty  of  medications  that  reduce  the  incidence  and  severity
f  myoclonic  movements  after  etomidate  administration,
he  mechanism  is  not  clear.  Doenicke  et  al.  reported  that
yoclonus  after  treatment  with  etomidate  was  a  phe-
omenon  of  subcortical  disinhibition,  like  the  phenomenon
f  restless  legs  during  normal  human  sleep,  and  is  not  gen-
rated  by  an  epileptic  focus.1,4
Gabapentin,  produced  in  1993  as  a treatment  for  chronic
artial  convulsions,  is  a  new  generation  of  anti-epileptic
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ith  antinociceptive,  analgesic  and  antihyperalgesic  prop-
rties.  The  most  widespread  use  of  gabapentin,  outside  of
pilepsy,  is  for  neuropathic  pain.5 Also  gabapentin  and  its
nalogs  have  been  effective  in  the  treatment  of  motion  dis-
rders  such  as  periodic  leg  movements  in  sleep,  restless
eg  syndrome,  essential  tremor  and  acquired  nystagmus.6
ecently  many  clinical  studies  evaluating  the  potential  role
f  gabapentin  in  the  preoperative  period  for  a  variety  of  aims
ave  been  published.5 However  though  myoclonus  linked  to
tomidate  has  similar  pathophysiology  and  EEG  results  as
estless  leg  syndrome  which  has  been  successfully  treated
y  gabapentin,  no  studies  were  found  on  gabapentin’s  effect
n  myoclonus  linked  to  etomidate.  The  hypothesis  of  this
tudy  is  that  pretreatment  with  three  different  doses  of
ral  gabapentin  will  reduce  the  incidence  and  severity
f  myoclonic  movements  linked  to  etomidate  in  a  dose-
ependent  fashion.
To  test  this  hypothesis  the  aim  was  to  complete
 prospective,  randomized,  double-blind  and  placebo-
ontrolled  study  to  research  the  effects  of  three  different
oses  of  oral  gabapentin  pretreatment  on  the  incidence  and
everity  of  myoclonic  movements  linked  to  etomidate.
ethods
his  study  was  completed  with  permission  of  Firat  University
edical  Faculty  Pharmaceutical  Research  Ethics  Committee
Head:  Prof.  Mehmet  Tokdemir,  dated  12.07.2012,  deci-
ion  n◦ 07)  between  July  2012  and  December  2012  in  the
perating  theaters  of  Firat  University  Medical  Faculty  and
kmeydani  Educational  and  Research  Hospital  after  patients
igned  an  informed  consent  form.  One-hundered  patients  in
--II  risk  group,  according  to  the  American  Society  of  Anes-
hesiologists  (ASA)  classiﬁcation  of  physical  condition,  who
ere  to  undergo  elective  surgical  intervention  under  gen-
ral  anesthesia  between  the  ages  of  18--60  were  included  in
he  study.
Patients  considered  have  airway  management  difﬁ-
ulties,  cardiac  disease,  diabetes  mellitus,  history  of
euromuscular  disease,  impaired  renal  status,  liver  failure,
OPD  and  asthma,  hiatal  hernia  and  symptomatic  gastro-
sophageal  reﬂux,  gastrointestinal  dysfunction  affecting
bsorption  of  oral  treatments,  history  of  allergic  reaction  to
he  study  drugs,  pregnancy,  lactating  female  patients,  drug
r  alcohol  addiction,  and  patients  with  a  history  of  chronic
pioid,  tricyclic  antidepressant,  benzodiazepine  anticon-
ulsant,  clonidine,  beta  blocker,  systemic  and/or  topical
teroid  use  were  not  included  in  the  study.
No  patient  received  any  premedication.  The  patients
ere  randomly  assigned  using  a  computer-generated  ran-
om  numbers  table  to  one  of  the  following  four  treatment
roups:  1  --  Group  P  received  an  oral  placebo;  2  --  Group
400  received  gabapentin  400  mg,  po;  3  --  Group  G800
eceived  gabapentin  800  mg,  po;  and  4  --  Group  G1200
eceived  gabapentin  1200  mg,  po.  The  study  medication
apsules  were  put  in  numbered  envelopes  containing  two
lacebo  capsules  (Group  P),  one  gabapentin  400  mg  with
ne  placebo  capsule  (Group  G400),  two  gabapentin  400  mg
apsules  (Group  G800),  or  two  gabapentin  600  mg  capsules
Group  G1200).  Two  hours  before  the  operation  study  med-
cations  were  administered  with  a  small  amount  of  water
H
a
o
KM.  Yılmaz  C¸akirgöz  et  al.
y  an  anesthetist  not  included  in  the  study.  The  study
rugs  were  prepared  by  the  pharmacy  in  order  to  maintain
ouble-blind  conditions,  and  an  appropriate  code  number
as  assigned.  Patients  and  the  anesthetist  in  charge  of
atient  management  and  data  collection  were  unaware  of
he  groups.  Before  being  taken  to  the  operating  room  side
ffects  developing  in  the  patients,  such  as  nausea,  vom-
ting,  dizziness,  headache,  confusion,  weakness,  fatigue,
ystagmus,  skin  rash,  drowsiness,  peripheral  edema,  vision
isorders  etc.,  were  evaluated  and  recorded  by  an  anes-
hetist  blind  to  the  contents  of  the  study  drugs  and  not
ncluded  in  the  study.
After  patients  were  transferred  to  the  operating  table
reoxygenation  was  begun  with  6  L  min−1 oxygen  admin-
stered  through  a  mask  and  non-invasive  blood  pressure,
lectrocardiogram,  and  pulse  oxymetry  monitoring  was
pplied.  A  vein  was  opened  in  the  back  of  the  left  hand
ith  a  20  G  cannula  and  infusion  of  0.9%  NaCl  solution
as  started.  After  preoxygenation  for  anesthesia  induction
.3  mg  kg−1 etomidate  was  administered  for  10  s.  After  the
yelash  reﬂex  was  lost  after  induction  the  patient  was  man-
ally  administered  100%  O2 through  a mask  until  end  tidal
O2 (ETCO2)  was  35--40  mmHg.  Two  minutes  after  induction
 g  kg−1 fentanyl  and  0.8  mg  kg−1 rocuronium  were  given  for
racheal  intubation.  After  endotracheal  intubation  anesthe-
ia  was  maintained  with  30%  oxygen,  70%  nitrous  oxide  with
%  sevoﬂourane.
Sedation  and  myoclonic  movements  were  evaluated  and
ecorded  on  a  0--3  scale  by  an  anesthetist  blind  to  the
tudied  medication.  Evaluation  of  sedation  was  completed
efore  induction  with  etomidate  was  begun;  sedation  level
as  evaluated  as  0  =  none/awake  (alert),  1  =  slight  (drowsy
ut  responds  to  name  said  in  normal  voice),  2  =  moderate
responds  to  loud  voice  and/or  repeated  calls)  and  3  =  deep
responds  when  prodded  lightly  or  shaken).2 Myoclonic
ovements  were  evaluated  in  the  2  min  period  after  induc-
ion;  myoclonic  severity  was  evaluated  according  to  0  =  no
yoclonus,  1  =  slight  myoclonus  (slight  fasciculation  of  face
nd/or  distal  upper  and/or  lower  extremities),  2  =  moderate
yoclonus  (deﬁnite  movements  of  face  and/or  extremities)
nd  3  =  severe  myoclonus  (movements  of  extremities  and
runk).7
Heart  rate  (HR),  mean  arterial  pressure  (MAP)  and  periph-
ral  oxygen  saturation  were  recorded  before  induction  (base
alue),  immediately  before  intubation  and  in  the  1st,  3rd
nd  5th  minutes  after  tracheal  intubation.  At  the  end  of  the
tudy  period,  anesthesia  management  was  transferred  to  the
nesthesia  team  responsible  for  the  operating  theater  and
ware  of  the  medications  administered  to  the  patient.
tatistical method
PSS  16.0  program  was  used  for  statistical  evaluation.  Con-
inous  data  were  evaluated  by  using  descriptive  statistics
mean,  median,  standard  deviation,  min--max).  For  eval-
ation  of  normally  distributed  data  between  groups  (age,
MI,  HR,  MAP)  one-way  ANOVA  and  Tukey  HSD  tests  (for  Post
oc  evaluation).  For  categorical  data  Pearson  Chi-square
nd  Fisher  Exact  test  (where  at  least  one  expected  value
f  a  cell  is  less  than  5)  were  used.  Mann  Whitney  U  test  and
ruskal  Wallis  tests  were  used  for  comparing  non-normally
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Table  1  Demographic  characteristics  of  patients.
Group  P  (n  =  25)  Group  G400  (n  =  25)  Group  G800  (n  =  25)  Group  G1200  (n  =  25)
Age  (years)  35.5  ±  12.4  34.9  ±  6.2  36.1  ±  9.4  35.8  ±  12.4
BMI (kg/m2)  24.0  ±  3.6  23.8  ±  3.0  23.9  ±  4.8  23.6  ±  3.3
Gender (male/female)  13/12  12/13  14/11  12/13
ASA physical  status  (I/II)  11/14  12/13  13/12  14/11
n. AS
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mData are given as number of patients or mean ± standard deviatio
distributed  data.  Signiﬁcance  was  accepted  as  p  <  0.05.  In
the  placebo  group  the  incidence  of  myoclonus  was  about
70%,  assuming  ˛  =  0.05,  and  1  −  ˇ  =  0.80,  and  with  a  pre-
dicted  average  reduction  of  myoclonus  incidence  of  40%8;
for  the  study  at  least  22  patients  were  required  in  each
group.  Working  from  this  data,  in  the  study  25  patients  was
included  in  each  group.
Results
In  terms  of  demographic  data  there  was  no  signiﬁcant  sta-
tistical  difference  between  the  groups  (p  >  0.05)  (Table  1).
In  the  two  hour  period  before  induction  other  than  sedation
none  of  the  side  effects  related  to  gabapentin  were  observed
in  any  patient.
There  was  a  signiﬁcant  difference  in  the  incidence,
severity  and  median  values  of  myoclonus  linked  to  etomi-
date  between  the  groups  (p  =  0.002  Chi-square,  p  =  0.006
Fisher  Exact  test,  Kruskal  Wallis  p  =  0.002  respectively).  The
myoclonus  severity  levels  in  the  G1200  and  G800  groups
were  signiﬁcantly  lower  than  in  Group  P  (p  =  0.006,  p  =  0.003
Fisher  Exact  test).  The  myoclonus  incidence  in  G1200  and
G800  was  signiﬁcantly  lower  than  in  Group  P  (p  =  001,
p  =  0.002  Chi-square),  and  in  Group  G800  the  incidence
was  signiﬁcantly  lower  than  in  Group  G400  (p  = 0.045  Chi-
square).  Compared  to  the  placebo  group,  in  G800  there  was
e
p
i
Table  2  Number  of  patients  (%)  and  severity  of  myoclonus  after  
Group  P  (n  =  25)  GroupG400
(n  =  25)
Severity  of  myoclonus  
None  (0)  6  (24)  11  (44)  
Mild  (1)  7  (28)  8  (32)  
Moderate  (2)  8  (32)  6  (24)  
Severe (3)  4  (16)  0  (0)  
Myoklonus (%)  19  (76)  14  (56)  
Severity  of  myoclonus
Median  (min--max)
(0--3)
1 (0--3)  1  (0--2)g
Relative  risk  (95%  CI)  1.36  (0.9--2.0)  
Group P, placebo group; Group G400, Gabapentin 400 mg; Group G800,
a Fisher exact test.
b Chi-square test.
c Kruskal Wallis test. Comparisons for incidence of myoclonus.
d p < 0.01 compared with group P.
e p < 0.05 compared with group G400. Comparisons for severity levels
f p < 0.02 compared with group P. Comparisons for severity of myoclo
g p < 0.05 compared with group P.A -- American Society of Anesthesiologists.
.71  times  and  in  G1200  there  was  2.38  times  less  myoclonus
bserved  (Table  2).
The  frequency,  intensities  and  median  values  of  sedation
etween  the  groups  were  statistically  signiﬁcantly  differ-
nt  (p  <  0.01).  The  frequency  and  intensities  of  perioperative
edation  in  Group  G1200  and  G800  were  signiﬁcantly  higher
han  in  Group  P  and  G400  (p  =  0.001,  p  =  0.001,  p  =  0.04,
 =  0.021  respectively)  (Table  3).  Compared  to  the  placebo
roup,  in  G800  there  was  4.76  times  and  in  G1200  there  was
.26  times  more  sedation  observed  (Table  2).
The  mean  arterial  blood  pressure  and  the  heart  rate
ere  similar  among  the  groups  at  all  measurement  times.
o  bradycardia  or  hypotension  was  observed  in  any  patient.
eripheral  oxygen  saturation  in  the  four  groups  during  the
tudy  period  was  above  ≥97%  and  there  was  no  signiﬁcant
ifference  observed  between  the  groups.
iscussion
n  this  study,  while  800  mg  and  1200  mg  of  gabapentin  2  h
efore  the  operation  reduced  the  frequency  and  severity  of
yoclonic  movements  linked  to  anesthesia  induction  with
tomidate,  it  was  determined  that  it  also  increased  the
reoperative  sedation  level.
Preventing  myoclonus  related  to  etomidate  is  clinically
mportant.  Etomidate  is  frequently  used  as  it  allows  early
injection  of  etomidate.
Group  G800
(n  =  25)
Group  G1200
(n  =  25)
p
0.006a
18  (72)f 17  (68)f
2  (8)f 3  (12)f
5  (20)  5  (20)
0  (0)  0  (0)
7  (28)d,e 8  (32)d 0.002b
0  (0--2)g 0  (0--2)g 0.002c
2.7  (1.39--5.28)  2.38  (1.29--4.38)
 Gabapentin 800 mg; Group G1200, Gabapentin 1200 mg.
 of myoclonus.
nus median.
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Table  3  Comparison  of  frequency  and  intensities  of  sedation  between  in  four  groups.
Group  P  (n  =  25)  Group  G400
(n  =  25)
Group  G800
(n  =  25)
Group  G1200
(n =  25)
p
Sedation  n  (%)  3  (12)  6  (24)  14  (56)c,d 16  (64)c,d <0.001a
Sedation  score  median  (0--3)  0  (0--1)  0  (0--1)  1  (0--1)c,d 1  (0--1)c,d <0.001b
Relative  risk  of  sedation
(95%  CI)  compared  with
Group  P
0.5  (0.14--1.78)  0.21  (0.7--0.66)  0.19  (0.06--0.56)
Group P, placebo group; Group G400, Gabapentin 400 mg; Group G800, Gabapentin 800 mg; Group G1200, Gabapentin 1200 mg.
Frequency of sedation.
a Chi-square test p < 0.001.
Intensities of sedation with four groups
b Fisher-exact test/Kruskal Wallis test p < 0.001.
c p < 0.002 compared with group P.
d p < 0.05 compared with group 400.
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tecovery  and  stable  hemodynamics  in  interventions  requir-
ng  short-term  anesthesia  like  elective  cardioversion.7 In
he  absence  of  neuromuscular  blocker  agents  when  used
or  induction  myoclonus  is  observed  in  50--80%  of  patients
ithout  premedication,  while  the  incidence  is  reported  as
0--45%  when  used  for  sedation  of  patients.1,9 Reported
ases  are  generally  mostly  minor  myoclonic  events  of
hort/brief  duration  or  tremor.  However  a  few  patients  have
yoclonic  events  characterized  as  serious,  described  as  gen-
ralized  rigidity  and  stiffness  and  lasting  several  minutes.  In
ddition  during  myoclonus  ECG  electrodes  were  displaced
nd  oxygen  saturation  falls  are  frequently  reported  on  pulse
xymetry.  In  this  situation  it  should  be  noted  that  myoclonic
vents  may  be  large  enough  to  delay  evaluation  of  mon-
toring  and  success  of  intervention  in  patients.3 However
specially  for  short  duration  interventions  the  medication
iven  to  prevent  myoclonus  due  to  etomidate  should  not
isrupt  the  positive  hemodynamic  and  early  recovery  prop-
rties  of  etomidate.2 In  our  study  at  the  doses  of  gabapentin
sed  no  effect  on  respiration  or  consciousness  after  the
ntervention  was  expected,  so  in  this  study  there  was  no
ostoperative  record  kept.
In  our  study,  similar  to  previous  studies,  observed
yoclonic  activity  at  76%  in  the  placebo  group.  It  is  known
hat  in  more  than  half  of  cases  myoclonus  due  to  etomi-
ate  starts  after  the  1st  minute1 so  the  observation  period
n  this  study  was  ﬁxed  at  2  min.  To  denote  the  difference
etween  hand-arm  pull  movements  due  to  pain  of  the  etomi-
ate  injection  and  myoclonus,  movement  during  intravenous
tomidate  administration  was  accepted  as  injection  pain,
hile  movement  in  the  2  min  after  the  injection  was  fully
nished  were  accepted  as  myoclonus.  It  is  known  from  previ-
us  studies  that  slow  injection  speed,  with  a  effect  similar  to
riming  dose  of  etomidate,  reduced  myoclonus  incidence.1
n  this  study  etomidate  was  injected  over  10  s.  It  is  thought
hat  this  allowed  us  to  capture  the  true  rate  of  myoclonus.
The  neurologic  mechanism  of  myoclonic  activity  after
tomidate  is  not  clear  and  one  possibility  is  that  it  may
e  a  form  of  seizure  activity.  Another  theory  is  that  its  ini-
ial  cause  may  be  due  to  differences  in  local  brain  blood
ow  or  in  receptor  afﬁnities  in  the  CNS  asynchronous  to  the
ffect  of  etomidate,  together  with  a  possible  subcortical
d
d
d
iisinhibition  developing  due  to  quick  suppression  of  corti-
al  inhibition  linked  to  earlier  and  lower  doses  depressing
he  excitatory  circuits  of  inhibitor  pathways.1,10 Disruption
f  GABA  neurons  makes  pathways  related  to  skeletal  muscle
ontrol  more  sensitive  to  spontaneous  nerve  transmissions,
hich  causes  myoclonic  muscle  movements.7 Choi  et  al.11
howed  that  rocuronium  premedication  blocked  the  neu-
omuscular  junction  transmission  and  deﬁnitively  reduced
yoclonus  due  to  etomidate.
Structurally  an  anticonvulsant  GABA  analog,  after  use  for
europathic  pain  syndromes,  in  the  1990s  gabapentin  began
o  be  used  successfully  to  treat  restless  leg  syndrome.12 The
xperimental  evidence  from  studies  to  date  indicate  a  dis-
nhibition  role  in  RLS  pathogenesis  at  supraspinal  levels.6 In
n  electroencephalogram  (EEG)  study  by  Doenicke  et  al.1 on
EG  epileptic  activity  was  not  encountered,  as  myoclonus
inked  to  etomidate,  similar  to  restless  leg  syndrome,  is
inked  to  subcortical  disinhibition  they  reported  that  low
oses  with  etomidate  administration  reduced  myoclonus,
upporting  the  subcortical  disinhibition  theory.  In  addition,
fter  premedication  with  benzodiazepans  and  opioids,  with
nown  limiting  effects  on  subcortical  structures,  the  reduc-
ion  in  myoclonus  linked  to  etomidate  supports  the  theory
f  disinhibition  of  subcortical  structures.1,4 While  the  effec-
ive  mechanism  of  gabapentin  is  not  deﬁnitely  known,  it
ncreases  non-synaptic  GABA  release  and  synthesis  from  glial
tructures  in  the  whole  brain  in  dose-linked  fashion.  Link-
ge  with  high  afﬁnity  for  2  subunits  of  voltage  sensitive
alcium  channels,  reduction  in  the  release  of  monoamine
eurotransmitters,  inhibition  of  voltage  active  sodium  chan-
els  and  increase  in  serotonin  concentration  are  among  the
ther  effects  proven  for  gabapentin.13 In  this  study  while  the
ncidence  of  myoclonus  in  Group  P  was  76%,  it  dropped  to
8%  and  32%  in  Group  G800  and  Group  G  1200  respectively.
n  the  groups  the  total  moderate  and  severe  myoclonus  inci-
ence  was  48%  in  Group  P,  24%  in  Group  G400,  and  20%  in
roup  G800  and  Group  G1200.  After  gabapentin  premedica-
ion,  the  reduction  in  severity  and  frequency  of  myoclonus
ue  to  etomidate  clearly  supports  reduction  in  subcortical
isinhibition  as  gabapentin,  similar  to  opioids  and  benzo-
iazepines,  increases  GABA  inhibition  in  the  whole  brain
ncluding  the  subcortical  structures.
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GABAA receptor-gated currents in cultured postnatal hippocam-
pal neurons. Neuroscience. 1996;73:69.
5. Tiippana EM, Hamunen K, Kontinen VK, et al. Do surgical
patients beneﬁt from perioperative gabapentin/pregabalin?Effect  of  gabapentin  pretreatment  on  myoclonus  after  etom
Gabapentin  is  a  medication  with  low  incidence  of
side  effects  and  little  interaction  with  other  medications
which  is  well  tolerated.  Non-epileptic  focal  and  multi-focal
myoclonus  is  among  the  side  effects  of  long-term  treat-
ment  with  gabapentin  and  pregabalin,  such  as  for  epilepsy,
neuropathic  pain  and  restless  leg  syndrome,  though  the
incidence  is  less  than  for  other  anticonvulsants.13 Recently
reports  of  myoclonus  related  to  gabapentin  (GBP)  use  been
case  studies  or  been  formed  of  small  patient  series.  In
available  case  studies,  frequently  a  clinical  tableau  of
myoclonus  a  few  days  after  gabapentin  dose  increase  from
stable  dose  in  cases  with  a  history  of  serious  neurologic
and/or  systemic  disease  and  polytherapy  administration,
which  quickly  resolves  within  days  after  stopping.  In  pre-
marketing  studies  of  1486  patients  using  gabapentin  for
epilepsy  a  myoclonus  rate  of  0.1%  was  reported.14 Contrary
to  this  Asconap  et  al.  when  inquiring  about  myoclonus  in
patients  receiving  gabapentin  treatment  found  12.5%  of  104
patients  had  observed  myoclonus.  This  high  incidence  may
be  partly  explained  by  questioning  speciﬁcally  for  myoclonic
situations.  In  the  patient  population  late  period  renal  fail-
ure  which  interferes  with  the  medications  renal  excretion,
chronic  static  encephalopathy,  mental  retardation  or  dif-
fuse  brain  damage  may  be  risk  factors  for  myoclonus  due
to  gabapentin.  This  relationship  is  known  from  the  devel-
opment  of  choreoathetosis  and  other  movement  disorders
during  use  of  gabapentin  and  other  antiepileptic  medi-
cations.  The  role  of  other  possible  risk  factors,  such  as
polytherapy  and  refractory  seizures  is  not  clear.14 The
anti-epileptic  effective  mechanism  of  gabapentin,  similar
to  its  induction  mechanism  for  myoclonus,  is  not  fully
understood.  Myoclonus  linked  to  gabapentin  is  thought  to
form  in  the  serotonergic  neurotransmitter  system  linked
to  myoclonus.15 In  addition,  in  posthypoxic  animal  models
a  dose-linked  antimyoclonic  effect  of  gabapentin  was
found.16 In  order  to  more  clearly  understand  the  relationship
between  gabapentin  and  myoclonus  more  advanced  stud-
ies  on  the  pathophysiology  of  myoclonus  and  the  effective
mechanism  of  gabapentin  are  needed.
In  the  peroperative  period  the  most  frequently  reported
side  effects  of  single-dose  or  short-term  gabapentin
administration  are  dizziness  (16%),  sedation  (23%),  nau-
sea/retching/vomiting  (19--25%),  somnolence,  urinary
retention,  and  lightheadedness.6 After  preoperative
gabapentin  administration  studies  on  the  presence  of  a
sedation  effect  in  the  preoperative  period  has  a  mixed
structure.  In  the  literature  for  a  variety  of  surgery  types,
600  or  1200  mg  gabapentin  in  the  preoperative  period
1--2  h  after  administration  in  the  limited  number  of  studies
evaluating  the  sedation  level,17--20 while  some  report  no  sta-
tistical  difference  in  sedation  level  between  placebo  group
and  gabapentin  group,  Clarke  et  al.21 in  a  study  evaluating
the  effect  of  1200  mg  gabapentin  2  h  before  operation  on
high-anxiety  levels  reported  observing  a  signiﬁcant  level
of  sedation  in  the  gabapentin  group  compared  to  the
placebo  group.  Together  with  this,  gabapentin’s  structural
analog  pregabalin  is  reported  to  increase  sedation  in  a
dose-linked  fashion  in  the  preoperative  period.22,23 In  this
study  in  the  2  hour  period  before  the  operation  similar  to
previous  studies,17--21 no  side  effects  linked  to  gabapentin
such  as  nausea  and  vomiting,  dizziness,  lightheadedness,
somnolence,  peripheral  edema,  and  visual  disturbances  ore  361
eadache  were  observed.  Comparing  the  frequency  and
ntensities  of  sedation  in  the  groups  in  the  preoperative
eriod,  a  deﬁnite  frequency  and  intensities  of  sedation  was
dentiﬁed  in  Group  G800  and  Group  G1200  compared  to
he  placebo  and  G400  group  (p  =  0.001,  p  =  0.001,  p  =  0.04,
 =  0.021  respectively).  The  results  of  this  study  are  similar
o  that  of  Clarke  et  al.21 in  that  increasing  dose  increased
edation  levels.
In  our  study  the  primary  limitation  is  that  the  patient
roup  was  younger  and  more  healthy  than  the  patient  group
o  whom  etomidate  is  most  frequently  administered  in  clin-
cal  practice.  Generalizations  should  not  be  made  from
his  study  for  high-risk  and/or  geriatric  patients  who  use
ntidepressants,  hypnotic  or  antihypertensive  medications,
ncluding  gabapentin,  who  may  show  increased  sensitivity  to
edication.  For  similar  future  research  more  advanced  stud-
es  are  needed  to  ﬁrstly  identify  the  optimal  dose  for  these
ypes  of  patients  and  possible  side  effects.  In  the  period
efore  surgery,  concerns  related  to  anesthesia  and  surgery
re  known  to  cause  anxiety  in  60--80%  of  patients.24,25 Stress
nd  anxiety  are  widely  accepted  to  delay  gastric  emptying.26
s  it  is  thought  that  absorption  of  orally  administered  med-
cation  and  peak  plasma  concentration  values  are  affected
y  anxiety,27 another  limitation  of  out  study  is  that  to  stan-
ardize  patients  basal  anxiety  levels  and  gabapentin  serum
evels  were  not  examined.
In  conclusion  in  this  study,  800  mg  and  1200  mg
abapentin  oral  administration  2  h  before  operation  reduced
he  frequency  and  severity  of  myoclonic  movements  dur-
ng  anesthesia  induction  with  etomidate  and  increased  the
edation  level  before  the  operation.  It  is  concluded  that
he  lowest  effective  dose  of  800  mg  gabapentin  should  be
onsidered  to  prevent  myoclonus  linked  to  etomidate.  How-
ver  the  sedative  properties  of  gabapentin  and  possibility  of
elaying  postoperative  recovery  in  cases  of  elective  ambu-
atory  surgery  should  be  noted.
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